AF710B
Cognition, Neuroprotection
Investigational compound, also known as ANAVEX3-71; human pharmacokinetics not publicly published.
In short
- Also called ANAVEX3-71. A muscarinic M1 receptor and sigma-1 receptor agonist developed for Alzheimer disease.
- Reported active at remarkably low doses in animal models — microgram-per-kilogram ranges.
- Preclinical only for most of its history; Anavex has since moved it into early human study.
- No published human pharmacokinetics or efficacy data.
- Research compound. The M1 and sigma-1 targets are legitimate CNS drug targets with real programmes behind them.
Structure
How it works
AF710B is an allosteric M1 muscarinic receptor agonist combined with sigma-1 receptor agonism.
M1 receptors are the principal postsynaptic muscarinic subtype in cortex and hippocampus, central to cholinergic signalling in memory. Selective M1 agonism has been a long-standing goal in Alzheimer drug development precisely because non-selective cholinergic drugs produce intolerable peripheral effects.
Sigma-1 is a chaperone protein at the endoplasmic reticulum-mitochondria interface, implicated in cellular stress responses and neuroprotection. Anavex's broader programme is built around sigma-1.
Preclinical reports describe effects on cognitive deficits, amyloid and tau pathology, and neuroinflammation at very low doses.
What the research shows
Rodent studies in models of Alzheimer disease report improvement in cognitive deficits and reductions in pathological markers at microgram-per-kilogram doses.
Anavex has advanced it into early clinical development. Published human efficacy or pharmacokinetic data is not available as of this review.
No evidence exists for cognitive effects in healthy people.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Rat — Alzheimer disease models | Reported active at approximately 10 µg/kg | oral or intraperitoneal | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 1–5 mg daily | oral |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The discrepancy here is large and worth noting: the compound is reported active in rodents at around 10 µg/kg, while community doses are in the low milligrams — several orders of magnitude higher on a body-weight basis than the animal data would suggest.
Handling and storage
Oral, as powder or capsules from research-chemical vendors.
No human route, timing, or duration has been established.
Side effects
No published human safety data.
The predictable class concern is cholinergic: M1 agonism can produce nausea, sweating, salivation, and gastrointestinal effects, which is exactly what limited earlier non-selective muscarinic agonists in Alzheimer trials. Selectivity is intended to reduce this and has not been demonstrated in published human data for this compound.
Sigma-1 agonism has a comparatively benign profile in the compounds studied so far.
Combinations
No interaction data. Combining with cholinesterase inhibitors or other cholinergic agents would be additive at the same system and is unstudied.
Research status
Preclinical work published by Abraham Fisher and colleagues, with Anavex Life Sciences advancing the sigma-1 platform including this compound.
The targets are legitimate and the science is published. Human data is not yet available.
Legal status
Not approved in any jurisdiction. Investigational. Sold as a research chemical.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
AF710B has credible targets, published preclinical work, and no human data in the public domain.
The gap between the microgram-per-kilogram doses that produced the animal results and the milligram doses circulating in community use is the specific thing worth pausing on — it suggests the community dosing was not derived from the research at all.
Sources
Track your own AF710B protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.